Sign in
Taking peopleNo phase

MEthylphenidate in ADHD - Addiction(s) Comorbidity: Value of Adding a Cognitive Remediation Program to Improve Short- and Medium-term Therapeutic Response

Key facts

Who runs it
Nantes University Hospital
Where
France6 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
248 people, planned
Started
11 Dec 2025
Expected to end
11 Dec 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Cognitive remediation program, with the PRESCO® software
  • Control program, with the AUDITICO® software
Record updated
19 February 2026

Who can take part

Age
18 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Age over 18
  • Diagnosis of ADHD confirmed by DIVA-5 interview following a specialized ADHD-addiction(s) consultation
  • Indication for MPH treatment according to European recommendations (J. J. S. Kooij et al., 2019) and absence of contraindications (particularly cardiological)
  • Presence of at least one comorbid addictive disorder (SUD and/or BA)
  • Having given their consent to take part in the study
  • Being affiliated to the French social security system or benefiting from such a system

Who cannot take part

  • Patients who consumned psychoactive substances within 12 hours prior to their visit
  • Presence of disorders of the higher functions or difficulties in reading or writing the French language making it impossible to collect data
  • Person under compulsory psychiatric care
  • Pregnant or breast-feeding woman
  • Person deprived of liberty
  • Participation in another interventional research protocol involving another psychotherapeutic or pharmacological intervention that may have an impact on clinical outcome
  • Guardianship or safeguard of justice

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

MEthylphenidate in ADHD - Addiction(s) comorbidity: benefit of adding a cognitive remediation program to improve short- and medium-term therapeutic response

The 2 groups in the trial

  • Cognitive remediation programTreatment being tested

    The cognitive remediation program under study (experimental treatment) consists of cognitive exercises performed on computers, in 30-45 minute sessions. The cognitive exercises target the deficits commonly observed in ADHD, a fortiori when it is associated with addictive disorders (working memory, inhibitory control, cognitive flexibility, attention, planning). The proposed program will be based on a software solution for cognitive rehabilitation, developed and validated for the treatment of attention and memory disorders and neurodegenerative, neurotraumatic and neuropsychiatric pathologies (PRESCO® software, marketed by HappyNeuron).

    Treatment: Cognitive remediation program, with the PRESCO® software

  • Control programExisting treatment, for comparison

    For the control program (comparator), we will use a software solution from the same company, but dedicated to stimulating and training auditory functions (AUDITICO® software). The advantage of this solution is that, like PRESCO®, it offers training exercises that are not aimed at re-educating cognitive functions. These include, for example, sound identification and discrimination activities. This tool can also be used by anyone, and is accessible for follow-up by the practitioner. It also offers levels of increasing difficulty, making it stimulating for users.

    Treatment: Control program, with the AUDITICO® software

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Fit questions
Built from NCT06906328, who can take part
Publications
Record updated
19 February 2026